Doctor profile · Federal record
Dr. Michael Lund, Physician Assistant
Emergency Medicine Physician (CMS: Physician Assistant) · Enfield, CT
- NPI 1306815980
- Accepts Medicare
- MIPS 97.5 / 100 · 2023
- 23 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
113 Elm Street, Suite 304
Enfield, CT 06082
(860) 741-2225
fax (860) 741-2229
Credentials & registration
- NPI registered
- March 2006 — 20 yrs on file
- Profile last updated
- August 11, 2021
- Year of graduation
- 2003 — 23 yrs since
- Specialty taxonomy
- 207P00000X — NUCC code
- State license (1)
- Connecticut #001367
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1306815980. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
2,726
Distinct HCPCS
10
Medicare allowed
$148,563
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
17003 |
Destruction of precancer skin growth, 2-14 growths | 1,092 | 209 | $6 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 550 | 436 | $116 | |
17000 |
Destruction of precancer skin growth, 1 growth | 373 | 289 | $53 | |
99213 |
Established patient office or other outpatient visit, 20-29 minutes | 262 | 215 | $82 | |
11102 |
Biopsy of related skin growth, first growth | 198 | 175 | $95 | |
99203 |
New patient office or other outpatient visit, 30-44 minutes | 61 | 61 | $102 | |
11103 |
Biopsy of related skin growth, each additional growth | 52 | 41 | $47 | |
96372 |
Injection of drug or substance under skin or into muscle | 50 | 14 | $13 | |
99202 |
New patient office or other outpatient visit, 15-29 minutes | 43 | 43 | $66 | |
17110 |
Destruction of skin growth, 1-14 growths | 32 | 30 | $105 |
In context: peer comparison
Among 1 peers in this city , average services per provider: 247. This provider delivers 11× the peer median.Open Payments
Industry payments received
All-time total
$3,335
Transactions
187
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| ABBVIE INC. | 24 | $485.65 | |
| Incyte Corporation | 15 | $414.76 | |
| Janssen Biotech, Inc. | 17 | $414.17 | |
| E.R. Squibb & Sons, L.L.C. | 23 | $389.08 | |
| Novartis Pharmaceuticals Corporation | 19 | $265.51 | |
| Lilly USA, LLC | 18 | $251.61 | |
| UCB, Inc. | 29 | $238.75 | |
| PFIZER INC. | 11 | $201.98 | |
| GENZYME CORPORATION | 6 | $199.04 | |
| Galderma Laboratories, L.P. | 14 | $153.81 | |
| LEO Pharma Inc. | 4 | $70.06 | |
| Dermavant Sciences, Inc. | 2 | $50.77 | |
| Arcutis Biotherapeutics, Inc. | 2 | $42.47 | |
| Amgen Inc. | 2 | $38.10 | |
| Regeneron Healthcare Solutions, Inc. | 1 | $34.97 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
955
Patients
555
Total drug cost
$537,713
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Triamcinolone Acetonide | Generic | 214 | 150 | $2,929 |
| Ketoconazole | Generic | 125 | 70 | $2,481 |
| Clobetasol Propionate | Generic | 89 | 47 | $6,346 |
| Doxycycline Monohydrate | Generic | 84 | 27 | $1,895 |
| Betamethasone Dipropionate | Generic | 80 | 49 | $6,442 |
| Imiquimod | Generic | 61 | 49 | $2,148 |
| Metronidazole | Generic | 61 | 23 | $6,961 |
| Desonide | Generic | 50 | 36 | $3,312 |
| Fluorouracil | Generic | 49 | 48 | $5,624 |
| Mupirocin | Generic | 33 | 24 | $259 |
Frequently asked questions
What is Dr. Michael Lund's medical specialty?
Dr. Michael Lund practices Emergency Medicine Physician in Enfield, CT.
Where does Dr. Michael Lund practice?
Dr. Michael Lund practices at 113 Elm Street, Enfield, CT 06082. Office phone: 8607412225.
What is Dr. Michael Lund's NPI?
Dr. Michael Lund's National Provider Identifier (NPI) is 1306815980, issued by NPPES.
Does Dr. Michael Lund accept Medicare assignment?
Yes. Dr. Michael Lund accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Michael Lund commonly perform?
Top Medicare-reported procedures in 2023: Destruction of precancer skin growth, 2-14 growths (HCPCS 17003); Established patient office or other outpatient visit (HCPCS 99214); Destruction of precancer skin growth, 1 growth (HCPCS 17000). Source: CMS Medicare Physician & Other Practitioners file.